The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology
Year: 2017
Type: editorial
Abstract: The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: IL1β Promotes Atheroprotective Changes in Late Stage Atherosclerotic Lesions, Oct4 and Klf4 regulate microvascular SMC-pericyte plasticity, angiogenesis, and metabolic dysfunction, Defining the role(s) of selective subsets of antigen presenting cells in promoting or preventing atherosclerosis (renewal), PDGFbeta Receptor Activation Promotes Atheroprotective Changes in SMC Phenotype, Role of IL1b in Regulating SMC and Macrophage Differentiation in Atherosclerosis, Defining SMC phenotypes critical in late stage atherosclerosis pathogenesis, Basic Cardiovascular Research Training Grant
OpenAlex ID: W2756894029
